ICD-10 Code C58: Malignant neoplasm of placenta (choriocarcinoma)

Key Takeaways

ICD-10 Code C58 is the billable diagnosis code for malignant neoplasm of placenta, most commonly choriocarcinoma, valid for reimbursement under 2026 ICD-10-CM guidelines.

C58 carries Female Dx and Maternity Dx (ages 12-55) edit restrictions in ICD-10-CM; applying it outside these parameters triggers claim edits.

Hydatidiform mole (O01.-) is excluded from C58 via a Type 1 Excludes note; the two codes must never appear on the same claim for the same condition.

Pabau’s claims management software and clinical documentation tools help gynecologic oncology teams code C58 accurately and reduce claim denials.

ICD-10 Code C58 is the billable ICD-10-CM diagnosis code for malignant neoplasm of the placenta, representing gestational choriocarcinoma. It sits within Chapter 2: Neoplasms (C00-D49), in the C51-C58 block of malignant neoplasms of female genital organs, and carries female-only and maternity (ages 12-55) edits.

OB/GYN and gynecologic oncology coders assign C58 whenever a confirmed gestational trophoblastic neoplasm (GTN) reaches the malignant classification threshold. This reference covers the 2026 ICD-10-CM details for C58: billable status, code hierarchy, inclusion terms, Type 1 Excludes notes, documentation requirements, and related codes.

Under the WHO’s ICD-10 classification, C58 represents malignant neoplasm of the placenta. In clinical practice, it is the primary code for choriocarcinoma of gestational origin: a malignant gestational trophoblastic neoplasm arising from pregnancy-related trophoblastic tissue. Coders working in OB/GYN EMR software encounter C58 once a confirmed GTN meets the malignant classification threshold.

Billable status and code attributes

C58 is a billable and specific ICD-10-CM code for 2026. It is valid for reimbursement purposes and carries no sub-codes; it is the terminal code in its category.

The Maternity Dx age edit (12-55) reflects the biological parameters of gestational trophoblastic disease. Claims submitted with C58 for patients outside this age range will typically trigger an automated payer edit. If a rare case genuinely falls outside the expected age window, coders should document the clinical rationale and follow payer-specific override procedures. The CDC/NCHS ICD-10-CM web tool provides the authoritative code descriptor flags for each annual release.

Code hierarchy: where C58 sits

C58 is a terminal (leaf) node in the ICD-10-CM hierarchy. It has no sub-codes. The path from chapter to code is:

1. Chapter 2: Neoplasms (C00-D49)
2. Block: Malignant neoplasms of female genital organs (C51-C58)
3. Category: Malignant neoplasm of placenta (C58-)
4. Code: C58 (billable, no further subdivision)

Because C58 has no sub-codes, coders do not need to select from a further specificity level. The code is both the category header and the only valid billable code in that category.

Inclusion terms and synonyms for C58

The ICD-10-CM tabular list carries choriocarcinoma NOS and chorionepithelioma NOS as the inclusion terms under C58. Coders encountering any of the following diagnoses in clinical documentation should map to C58 when the neoplasm originates from gestational trophoblastic tissue:

• Choriocarcinoma (gestational origin)
• Choriocarcinoma of placenta
• Gestational trophoblastic neoplasm (GTN) when malignant
• Malignant trophoblastic tumor of gestational origin
• Trophoblastic tumor, malignant (placental site, gestational)

An important distinction: choriocarcinoma in C58 refers specifically to gestational choriocarcinoma arising from pregnancy-related trophoblastic tissue. Non-gestational choriocarcinoma, for example arising from a gonadal germ cell tumor, is classified separately, and male choriocarcinoma maps to C62.9-.

The clinical documentation must support gestational origin for C58 to be appropriate. Coding teams using clinical documentation tools within their EHR can flag this distinction at the point of note review, reducing morphology-based coding errors.

Type 1 Excludes notes: What C58 does not cover

The Type 1 Excludes note on C58 is a hard coding rule, not a suggestion. Under ICD-10-CM convention, a Type 1 Excludes note means the excluded condition is “not coded here” and the two codes must never appear on the same claim for the same episode of care representing the same condition.

The Type 1 Excludes note for C58 specifies:

This distinction matters practically. A patient presenting with a molar pregnancy complicated by persistent hCG elevation requires clinical evaluation to determine whether the diagnosis has progressed to a confirmed GTN (C58) or remains at the molar stage (O01.-).

Coders should never upgrade from O01.- to C58 without explicit clinician confirmation of malignant transformation. The same Type 1 Excludes discipline applies to neighboring codes in the block, such as ICD-10 Code C51.0 for malignant neoplasm of the vulva: these notes are non-negotiable coding rules, not optional guidance.

ICD-10 Code C58 documentation requirements

Accurate C58 coding depends on specific elements being present in the clinical record before the code is assigned. Missing documentation is the leading cause of C58 claim denials in gynecologic oncology billing. According to CMS ICD-10-CM coding guidance, codes in Chapter 2 require documented clinical confirmation of malignancy before assignment.

Required documentation elements

• A confirmed diagnosis from the treating clinician. A gynecologic oncologist (or oncology-trained OB) must clearly document malignant GTN, choriocarcinoma, or equivalent. Coders cannot infer it from a high hCG alone.
• Gestational (pregnancy-related) origin. The tumor must come from trophoblastic tissue tied to a pregnancy. This is what separates C58 from non-gestational choriocarcinoma, which is coded elsewhere.
• Diagnostic confirmation. Either pathology showing choriocarcinoma, or imaging plus serial beta-hCG results with the clinician’s interpretation. (Same “confirm before coding” rule that applies to solid-tumor codes like C20 for rectal cancer.)
• FIGO stage, when available. Staging doesn’t change the code — C58 applies at every stage — but it supports medical necessity and chemotherapy authorization.
• Serial beta-hCG values. Trend results should be in the record. Payers often require them to approve methotrexate or combination chemo.

Practices using structured compliance management workflows within their EHR can build documentation checklists that prompt clinicians to record these elements before sign-off, reducing retrospective queries and coding lag time. The same documentation-first principle applies across all ICD-10 diagnostic codes: the code follows the documented diagnosis, never precedes it.

Streamline gynecologic oncology coding with Pabau

Pabau helps OB/GYN and gynecologic oncology practices manage clinical documentation, claims submissions, and compliance workflows in one platform. Reduce C58 coding errors before they reach the payer.

Book a demo

Related codes and C58 crosswalks

C58 rarely appears in isolation on a claim. Gynecologic oncology coding teams routinely need to identify the right companion codes for associated conditions, procedures, and secondary diagnoses. Because choriocarcinoma is highly metastatic, coders may also reach for secondary-site codes such as ICD-10 Code C77.8 for secondary malignant neoplasm of lymph nodes when the disease has spread.

Codes within the C51-C58 block (female genital neoplasms)

• C51. Malignant neoplasm of vulva
• C53. Malignant neoplasm of cervix uteri (C53.0 endocervix, C53.1 exocervix)
• C54. Malignant neoplasm of corpus uteri
• C55 Malignant neoplasm of uterus, part unspecified
• C56. Malignant neoplasm of ovary (C56.1 right, C56.2 left, C56.9 unspecified)
• C57. Malignant neoplasm of other and unspecified female genital organs
• C58. Malignant neoplasm of placenta (this code)

Key excluded and related obstetric codes

When a patient with a history of choriocarcinoma presents for serum hCG surveillance after completing chemotherapy, the encounter code Z08 typically leads rather than C58, unless active disease is still documented. Coding the follow-up with C58 when the patient is in remission overstates current disease status and can complicate insurance records. Practices managing patient data security in clinical settings should ensure historical diagnosis codes are clearly separated from active encounter diagnoses in the record to avoid this common billing error.

Coding guidelines and workflow guidance for C58

Several practical workflow decisions arise regularly in gynecologic oncology billing when working with ICD-10 Code C58. The official CMS guidelines govern these decisions, but the operational questions below reflect what coders most frequently encounter.

Sequencing C58 as principal vs. secondary diagnosis

C58 should be sequenced as the principal diagnosis when the reason for the encounter is the GTN itself: chemotherapy administration, staging workup, or initial evaluation of a confirmed malignancy. When the patient presents for a complication of treatment (for example, chemotherapy-induced nausea or methotrexate toxicity), the complication code leads and C58 becomes a secondary diagnosis.

Encounters specifically for chemotherapy administration use Z51.11 (encounter for antineoplastic chemotherapy) as the principal code with C58 as secondary. This sequencing convention follows the ICD-10-CM Official Guidelines for Coding and Reporting, which specify that when the reason for admission is the administration of chemotherapy, the treatment encounter code sequences first.

ICD-10-CM vs. ICD-O-3 distinctions for oncology coders

Oncology registrars and cancer registry staff use the International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3) alongside ICD-10-CM. ICD-O-3 records tumor morphology (histological type) and topography (site) separately.

Choriocarcinoma in ICD-O-3 carries morphology code 9100/3, which maps to the placental topography code C58.9 in ICD-O-3 notation. These are not interchangeable with ICD-10-CM C58; the ICD-O-3 codes are used in cancer registry submissions, not on HIPAA-mandated billing transactions.

Billing teams should use ICD-10-CM C58 for all HIPAA-covered claim transactions. Cancer registry staff submit ICD-O-3 codes separately to the relevant registry (for example, SEER in the US). Conflating these two systems is a common source of documentation confusion in multidisciplinary oncology practices. The HIPAA compliance requirements for medical offices are clear that only ICD-10-CM codes are valid for claim submission under the standard transaction sets.

NHS and UK context for C58

In the UK, the NHS National Disease Registration Service (NDRS) classifies gestational trophoblastic neoplasms under ICD-10 C58, consistent with the WHO version of ICD-10. UK practices use the WHO’s ICD-10 (not the US ICD-10-CM), and the NHS Classifications Browser provides the UK-specific implementation.

The clinical definitions align closely between ICD-10 and ICD-10-CM for C58. However, the US-specific maternity age edit and Female Dx restriction are ICD-10-CM features that do not apply to ICD-10 (WHO) submissions in UK NHS settings.

Practices operating across US and UK contexts should confirm which coding system governs each submission. Billing for NHS-funded episodes uses ICD-10 (WHO version); US private payer and Medicare claims require ICD-10-CM. Using claims management software that supports multi-jurisdiction coding helps reduce cross-system errors when teams operate in both markets.

Supporting documentation and EHR workflows for C58

Accurate C58 coding does not happen at the point of claim submission; it happens at the point of clinical documentation, increasingly supported by AI clinical documentation tools. The documentation workflow upstream determines whether the code can be defended at audit.

Structured intake and clinical forms

Gynecologic oncology practices benefit from structured intake workflows that capture gestational history, prior molar pregnancy, serum hCG trend data, and pathology confirmation in discrete fields. Structured data is easier to audit, extract for registry submissions, and review for coding accuracy than free-text narrative notes.

Using digital intake and consent forms that map to the clinical elements required for C58 documentation reduces retrospective queries to clinicians. Choosing the right gynecology EHR makes it easier to build these condition-specific templates.

The role of structured medical forms in healthcare practice is particularly significant in oncology, where incomplete documentation can affect not only billing but also cancer registry submissions and treatment authorization. Pabau’s digital forms let practices prompt clinicians for the exact elements coders need.

Automated coding support and claim scrubbing

Modern EHR and practice management platforms can run pre-submission claim checks that flag potential coding issues, including age/gender edits on codes like C58, missing required companion codes, and sequencing conflicts. These automated checks catch issues before the claim leaves the practice, reducing first-pass denial rates without additional coder effort.

Pabau’s claims management tools support gynecologic oncology workflows by linking clinical notes to diagnosis code selection and flagging missing documentation before submission. Teams comparing options can review what medical billing involves and our overview of the best medical billing software in the US to align coding and revenue-cycle workflows.

Conclusion

ICD-10 Code C58 is a precise, single-code category for malignant neoplasm of the placenta: no sub-codes, a hard Type 1 Excludes note separating it from hydatidiform mole, and strict Female Dx and Maternity Dx age edits that trigger payer rejections when violated. Getting C58 right requires confirmed malignancy documentation, clear gestational origin, and correct sequencing based on encounter purpose.

Practices that standardize their documentation workflows upstream, from structured intake forms to pre-submission claim checks, see fewer denials and cleaner audit trails. Pabau’s integrated claims management and digital forms features support exactly that workflow for OB/GYN and gynecologic oncology teams. Book a demo to see how Pabau handles oncology documentation and coding workflows in practice.

Continue your research

Looking for structured clinical notes guidance? Safer clinical notes outlines how to structure documentation to support coding accuracy and reduce audit risk.

Frequently asked questions